Biogen Idec has filed a biologics license application with the FDA for approval to use its interferon-based drug Plegridy as a treatment for relapsing forms of multiple sclerosis. The application was based on data from a late-stage trial indicating that Plegridy significantly reduced disease activity. Biogen also plans a European application within weeks.
Biogen submits MS drug candidate Plegridy for FDA approval
SmartBrief Job Listings for Health Care
|Director, Quality Assurance||
|Provider Relations Manager||
Breakthrough Behavioral, Inc.
|Redwood City, CA|
|Director Account Management||
Samaritan Health Services
|Hospital Medical Device Sales||
Linda Hertz Group